Investor's Business Daily on MSN
CRISPR Therapeutics stock sees RS rating rise to 73
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
In a world where agriculture is confronted with unprecedented challenges—such as climate variability, emerging pathogens, and ...
New Early Access Express License provides streamlined, affordable access to foundational CRISPR/Cas9 intellectual property to ...
In a world where agriculture is confronted with unprecedented challenges—such as climate variability, emerging pathogens, and soil degradation, in addition ...
At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases.
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
Durham, North Carolina and Oxford, United Kingdom, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pairwise, a global innovator in agriculture, today ...
Similar to the trends during the last few weeks, Cathie Wood’s ARK exchange-traded funds continued to step up bets on AI and ...
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are ...
CRISPR Therapeutics is a better buy right now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results